A 26-Week, 2-Part Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
Status:
Active, not recruiting
Trial end date:
2022-03-19
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety, tolerability and pharmacokinetics (PK) of
PF-06882961 in adults with obesity. The first part of the study, Part A, consists of study
treatment dosing in Weeks 1 to 16. The second part of the study, Part B, is planned such that
participants in Part A will continue dosing from Weeks 17 through 26, contingent upon
supportive data. The planned End of Treatment is expected to be Week 26. If Part B is not
conducted, then End of Treatment will be Week 16.